COSCIENS Biopharma Q4 2024 Earnings Report

COSCIENS Biopharma EPS Results

• Actual EPS: -$2.15
• Consensus EPS: -$3.48
• Beat/Miss: Beat by +$1.33
• One Year Ago EPS: N/A

COSCIENS Biopharma Revenue Results

• Actual Revenue: $3.32 million
• Expected Revenue: $1.10 million
• Beat/Miss: Beat by +$2.22 million
• YoY Revenue Growth: N/A

COSCIENS Biopharma Announcement Details

• Quarter: Q4 2024
• Date: 4/9/2025
• Time: Before Market Opens
• Conference Call Date: Wednesday, April 9, 2025
• Conference Call Time: 8:00AM ET

COSCIENS Biopharma (NASDAQ:CSCI), a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis. The company also has a license and research agreement with University of Wuerzburg to develop, manufacture, and commercialize AIM biologicals for the treatment of neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson's disease. In addition, it has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria Eood for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults; as well as The University of Sheffield, the United Kingdom for the development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of chronic hypoparathyroidism. The company was formerly known as Aeterna Zentaris Inc. and changed its name to COSCIENS Biopharma Inc. in August 2024. COSCIENS Biopharma Inc. was incorporated in 1990 and is headquartered in Toronto, Canada.